Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
2020 ◽
Vol 20
◽
pp. S258-S259
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):